Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Rio de Janeiro; s.n; 2017. 63 f p. tab, graf, il.
Thesis in Portuguese | LILACS | ID: biblio-995881

ABSTRACT

De acordo com os dados do Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA), foram esperados, no Brasil, 61.200 novos casos de câncer de próstata para o ano de 2016. Estabelecido o diagnóstico, as opções terapêuticas são consideradas e se baseiam no estadiamento, dosagem do antígeno prostático específico (PSA) e escore histológico de Gleason. Segundo as diretrizes diagnósticas e terapêuticas do adenocarcinoma de próstata publicadas (2015), a técnica de radioterapia de intensidade modulada (IMRT) apresenta benefício no controle da doença e a menor probabilidade de toxicidade. Este trabalho teve como objetivo analisar a custo-efetividade da técnica de IMRT, na perspectiva do SUS, para o tratamento do câncer de próstata localizado, comparada com a técnica conformacional (3DRT). Foi construído um modelo de Markov e, uma coorte hipotética de homens de 65 a 70 anos foi acompanhada por 10 anos. A medida de desfecho clínico foram os anos de vida ajustados para qualidade (QALY). Os custos levantados se basearam nos valores da tabela APAC para um tratamento na dose de 74 a 76 Gy. Análise de sensibilidade probabilística baseada em simulação de Monte Carlo a fim de construir um limiar de aceitabilidade para incorporação da tecnologia em questão foi desenvolvida. O uso da tecnologia IMRT proporcionou um incremento de 0,79 QALY, mas não se mostrou custo-efetiva em relação aos pacientes que receberam radioterapia pela 3DRT. A IMRT apresentou uma razão de custoefetividade incremental de R$10.580,98/QALY. Ao considerar um limiar de aceitabilidade de três vezes o produto interno bruto (PIB) per capita, segundo recomendação da Organização Mundial de Saúde (2011), estimado em R$ 86.628,00/QALY, para 2016, o cenario para a incorporaçao dessa tecnologia se apresenta favoravel. A probabilidade do IMRT ser custo-efetiva foi de 72,5% para limiares de aceitabilidade de R$15.000,00


According to data from the Coordination of Prevention and Surveillance of the National Cancer Institute José Alencar Gomes da Silva (NCI) 61,200 new cases of prostate cancer were expected in Brazil in 2016. Once the diagnosis is established, the therapeutic options are considered according to risk groups described by D'Amico (1998), which are based on staging, prostate-specific antigen (PSA) and Gleason score. For localized prostate tumors, and for all risk groups, radiotherapy is indicated. According to the diagnostic and therapeutic guideline of prostate adenocarcinoma published in October 2015, the intensity modulated radiotherapy (IMRT) technique has a benefit in controlling the disease and the lower probability of toxicity. According to this premise, this study aimed to analyze the costeffectiveness of the IMRT technique, from the perspective of SUS, for the treatment of localized prostate cancer, compared with three-dimensional technique (3DRT). A mathematical model based on Markov models was constructed and a hypothetical cohort of men aged 65 to 70 years was followed up for 10 years. A probabilistic sensitivity analysis was performed based on Monte Carlo simulation to construct a threshold of acceptability for incorporation of the technology in question. As a result of the study, the use of IMRT technology provided a 0.79-year increase in quality-adjusted life years (QALY), but was not cost-effective compared to patients who received radiotherapy using the 3DRT. The IMRT presented an incremental cost-effectiveness ratio of R $ 10,580.98 / QALY. Based on a threshold of three times the per capita GDP, according to the WHO recommendation (2011), calculated at R $ 86,628.00 / QALY for 2016, the scenario for the incorporation of this technology is favorable. If a threshold of acceptability of R $ 28,876 is considered equivalent to a GDP per capita, the probability of IMRT being cost-effective is 72%


Subject(s)
Humans , Male , Aged , Prostatic Neoplasms/radiotherapy , Prostatic Neoplasms/epidemiology , Unified Health System , Brazil , Case-Control Studies , Cost-Benefit Analysis , Radiotherapy, Conformal/statistics & numerical data , Radiotherapy, Intensity-Modulated/economics
2.
Rev. chil. neurocir ; 42(2): 133-136, nov. 2016. ilus
Article in Spanish | LILACS | ID: biblio-869764

ABSTRACT

Introducción: Los meningiomas de la vaina del nervio óptico (MVNO) son tumores inusuales de la vía visual anterior. Sin tratamiento, el crecimiento del tumor lleva a pérdida visual progresiva hasta la ceguera debido a la compresión que ejerce sobre el nervio óptico. Presentación del caso: Paciente, sexo femenino, 42 años, sin antecedentes mórbidos, que en 1992, inicia cuadro de disminución de la agudeza visual del ojo izquierdo. La resonancia magnética (RM) cerebral informa una lesión expansiva fusiforme en relación a la vaina del nervio óptico izquierdo que lo engloba, altamente sugerente de MVNO. En esa ocasión se realiza exploración de órbita la cual resulta frustra, por lo que se decide observación con controles clínicos e imagenológicos anuales, permaneciendo estable. Aproximadamente diez años más tarde, en el lapso de un año, inicia agravación progresiva de la agudeza y campo visual, ptosis palpebral y alteraciones de la oculo-motilidad del ojo izquierdo, objetivadas por examen neuro-oftalmológico, por lo que se sospecha progresión de MVNO. Se solicita nueva RM que confirma crecimiento significativo del tumor. Se descarta nuevo abordaje quirúrgico por riesgo de mayor deterioro visual y se efectúa radioterapia conformacional con una dosis de 54 Gy. Actualmente, a la edad de 65 años, se cumplen 24 años de evolución, 13 post radioterapia, confirmándose estabilidad clínica y radiológica de MVNO. Discusión: La radioterapia, cuando se observa progresión de la enfermedad, ha demostrado ser una terapia eficaz para los MVNO, con menos complicaciones y con mejores resultados en la preservación de la función visual a largo plazo.


Introduction: Optic nerve sheath meningiomas (ONSM) are rare tumors of the anterior visual pathway. Without treatment, tumor growth leads to progressive loss of visual acuity and blindness due to optic nerve compression. Case report: Patient, female, 42 years without other morbility , begins in 1992 with decreased visual acuity of the left eye, magnetic resonance imaging (MRI) showed enlargement of the left optic nerve sheath, suggestive of ONSM. On that occasion, orbit exploration failed, so it was decided to follow up with annual clinical and imaging controls. About ten years later, begins with progressive deterioration of visual acuity and visual field , with ptosis and ocular motor palsy of the left eye, confirmed with neuro-ophtalmological examinations. MRI shows tumor progression. A new surgical approach was discarded by the risk of visual worsening. A conformal radiotherapy was performed with a fractionated 54 Gy dose. Today, at age 65, after 24 years of follow up,13 post radiation therapy. clinical and radiological stability of ONSM is confirmed. Discussion: Conformal radiotherapy has been shown as an effective therapy, with fewer complications and better outcomes in the preservation of visual function in the long term follow up.


Subject(s)
Humans , Adult , Female , Magnetic Resonance Spectroscopy/methods , Meningioma/diagnosis , Meningioma/radiotherapy , Optic Nerve Neoplasms , Radiotherapy, Conformal , Radiosurgery/instrumentation , Radiosurgery/methods , Diagnostic Imaging/methods , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL